⌘K
Loading ticker…
As of 2026-08-24, Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI) has a 3-month relative strength percentile of 98 and a leadership percentile of 98 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 89. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.5%, relative volume 1.96×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
MRVI is in a stage 2 uptrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 33.3% / 96.4%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
MRVI is held by 18 ETFs as of May 2026. Top owner: SCHA at 0.01% weight, $3M notional. Top 3 carry $7M.
Held by 35 ETFs · $40M across latest filings · largest weight 0.76% (NIXT).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $3M | — |
| VTWO | 0.02% | $3M | — |
| VHTVanguard Health Care ETF | 0.01% | $2M | — |
| VTWV | 0.03% | $421K | — |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $390K | — |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| GNOM | 0.51% | $282K | +0.19 pp |
| GINN | 0.08% | $176K | new |
| QQQS | 0.55% | $104K | +0.09 pp |
| VTHRVanguard Russell 3000 ETF | 0.00% | $39K | — |
| IBBQ | 0.06% | $37K | +0.02 pp |
Showing 10 of 18 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MRVI Jan avg: -3.79% median: -3.55% win: 50% σ: 7.79% n: 4 2022-04-12 → 2026-07-31 | MRVI Feb avg: 1.29% median: 3.28% win: 75% σ: 27.93% n: 4 2022-04-12 → 2026-07-31 | MRVI Mar avg: -11.18% median: -12.76% win: 25% σ: 18.95% n: 4 2022-04-12 → 2026-07-31 | MRVI Apr avg: -0.57% median: -5.42% win: 20% σ: 18.06% n: 5 2022-04-12 → 2026-07-31 | MRVI May avg: 8.41% median: 5.73% win: 80% σ: 14.01% n: 5 2022-04-12 → 2026-07-31 | MRVI Jun avg: 1.54% median: -3.19% win: 40% σ: 18.23% n: 5 2022-04-12 → 2026-07-31 | MRVI Jul avg: 4.22% median: -2.90% win: 40% σ: 18.60% n: 5 2022-04-12 → 2026-07-31 | MRVI Aug avg: -8.04% median: -7.78% win: 25% σ: 9.59% n: 4 2022-04-12 → 2026-07-31 (current) | MRVI Sep avg: 7.36% median: 7.65% win: 50% σ: 15.33% n: 4 2022-04-12 → 2026-07-31 | MRVI Oct avg: -16.95% median: -21.12% win: 25% σ: 20.54% n: 4 2022-04-12 → 2026-07-31 | MRVI Nov avg: -11.05% median: -16.92% win: 25% σ: 18.82% n: 4 2022-04-12 → 2026-07-31 | MRVI Dec avg: 2.63% median: -3.85% win: 25% σ: 17.46% n: 4 2022-04-12 → 2026-07-31 |